Jeff Jonker has been appointed president and CEO of Ambys Medicines. Jonker comes to the Redwood City, CA-based biotech from NGM Bio, where he was president. His experience also includes senior positions at Theravance Biopharma (NASDAQ: [[ticker:TBPH]]), Satori Pharmaceuticals, and Genentech. Ambys is developing treatments for liver diseases. In August, Ambys launched with a $60 million Series A funding round and a broad partnership with Takeda Pharmaceutical (OTCMKTS: [[ticker:TKPYY]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
